News Hour

Rafiuzzaman Sifat

Md. Rafiuzzaman Sifat, a CSE graduate turned into journalist, works at News Hour as a staff reporter. He has many years of experience in featured writing in different Bangladeshi newspapers. He is an active blogger, story writer and social network activist. He published a book named 'Se Amar Gopon' inEkushe boi mela Dhaka 2016. Sifat got a BSc. from Ahsanullah University of Science & Technology, Bangladesh. He also works as an Engineer at Bangla Trac Communications Ltd. As an avid traveler and a gourmet food aficionado, he is active in publishing restaurant reviews and cutting-edge articles about culinary culture.

Mandarin oriental, Barcelona and world class to open pdt (please don’t tell) pop-up cocktail bar at the hotel

by Rafiuzzaman Sifat - Aug 10, 2016

News Hour: Mandarin Oriental, Barcelona and WORLD CLASS, the luxury collection of spirits from Diageo RESERVE, are opening a pop-up bar. The hotel’s Banker’s Bar will be made-over to recreate PDT (Please Don’t Tell), the legendary...
The spa at mandarin oriental, atlanta introduces the unveil your best self package

by Rafiuzzaman Sifat - Aug 10, 2016

News Hour: The Spa at Mandarin Oriental, Atlanta is pleased to offer the Unveil Your Best Self package in partnership with West Coast Workout. Get wedding ready before the big day with a comprehensive body and...
Wyndham vacation ownership named among healthiest employers in Central Florida

by Rafiuzzaman Sifat - Aug 10, 2016

News Hour: Wyndham Vacation Ownership (WVO), the world’s largest vacation ownership company and a member of the Wyndham Worldwide family of companies (NYSE: WYN), was recently recognized by Orlando Business Journal as one of the “Healthiest...
Ascott marks its 10th anniversary in hong kong with the opening of citadines harbourview and the newly-rebranded citadines mercer

by Rafiuzzaman Sifat - Aug 10, 2016

News Hour: CapitaLand’s wholly-owned serviced residence business unit, The Ascott Limited (Ascott) has unveiled two Citadines properties in Hong Kong. With the opening of the 52-unit Citadines Harbourview Hong Kong and the newly-rebranded 55-unit Citadines Mercer...
Ascott opens first citadines serviced residence in seoul to cater to the rise of independent travellers

by Rafiuzzaman Sifat - Aug 10, 2016

News Hour: CapitaLand’s wholly owned serviced residence business, The Ascott Limited (Ascott), has opened its first Citadines-branded property in Korea’s capital, Citadines Han River Seoul. The opening of the 149-unit Citadines Han River Seoul marks Ascott’s...
Notice regarding completion of share transfer of an affiliated company accounted for by the equity method

by Rafiuzzaman Sifat - Aug 9, 2016

News Hour: Otsuka Holdings Co., Ltd. (“Otsuka Holdings”) announces that its indirectly owned subsidiary Giant Harvest, Ltd. (“GHL”; Otsuka Pharmaceutical Co., Ltd.’s subsidiary) has completed the transfer of all of GHL’s shares of VV Food &...
Biogen reports second quarter 2016 revenues of $2.9 billion

by Rafiuzzaman Sifat - Aug 9, 2016

News Hour: Biogen Inc. (NASDAQ: BIIB) reported second quarter 2016 financial results, including: Total revenues of $2.9 billion, a 12% increase versus the same period in the prior year. Growth was driven by increases in worldwide...
SB5, an adalimumab biosimilar referencing humira®, accepted for review by european medicines agency

by Rafiuzzaman Sifat - Aug 9, 2016

News Hour: The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira®, has been accepted for review by the European Medicines Agency (EMA). The MAA for SB5 is the third anti-TNF biosimilar candidate...
Once-monthly Zinbryta™ (Daclizumab) approved in European Union for treatment of Multiple Sclerosis

by Rafiuzzaman Sifat - Aug 9, 2016

News Hour: The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced last month....
Interim analysis of phase 3 endear study in infantile-onset spinal muscular atrophy

by Rafiuzzaman Sifat - Aug 9, 2016

News Hour: Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen...

« Previous 1 … 61 62 63 64 65 … 109 Next »

Rafiuzzaman Sifat

Mandarin oriental, Barcelona and world class to open pdt (please don’t tell) pop-up cocktail bar at the hotel

The spa at mandarin oriental, atlanta introduces the unveil your best self package

Wyndham vacation ownership named among healthiest employers in Central Florida

Ascott marks its 10th anniversary in hong kong with the opening of citadines harbourview and the newly-rebranded citadines mercer

Ascott opens first citadines serviced residence in seoul to cater to the rise of independent travellers

Notice regarding completion of share transfer of an affiliated company accounted for by the equity method

Biogen reports second quarter 2016 revenues of $2.9 billion

SB5, an adalimumab biosimilar referencing humira®, accepted for review by european medicines agency

Once-monthly Zinbryta™ (Daclizumab) approved in European Union for treatment of Multiple Sclerosis

Interim analysis of phase 3 endear study in infantile-onset spinal muscular atrophy

Facebook

Twitter